All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub were pleased to speak to Jean-Jacques Kiladjian, University of Paris, Paris, FR, during the 61st American Society of Hematology (ASH) meeting in Orlando, US. Based on the PROUD-PV/CONTINUATION-PV studies, we asked: What are the benefits of ropeginterferon alpha-2b for the treatment of polycythemia vera?
Jean-Jacques Kiladjian discusses the results of the phase III, randomized, PROUD-PV and its extension study, CONTINUATION-PV, in patients with polycythemia vera in need of a cytoreductive treatment such as the long-acting ropeginterferon alpha-2b. He explains the response rates, clinical benefits and superiority of the ropeginterferon alpha-2b treatment against the comparator arm.
PROUD-PV/CONTINUATION-PV studies: benefits of ropeg IFN alfa-2b for the treatment of PV
PROUD-PV phase III results on ropeginterferon alpha-2b for polycythemia vera
Interferon alpha (IFN-a) compounds have long been used for the treatment of myeloproliferative neoplasms (MPN), showing a combination of clinical, molecular, and...
What is the news about ropeginterferon?
During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR, about ropeginterferon alfa-2b.
Subscribe to get the best content related to MPN delivered to your inbox